Pathological hypersexuality induced by dopamine replacement therapy in a patient with progressive supranuclear palsy.

نویسندگان

  • Yang Yeol Kim
  • Hye Yoon Park
  • Jong Min Kim
  • Ki Woong Kim
چکیده

Case Report A 78-year-old Indian man presented to us with a moderate depressive episode for 1 month. He had two previous episodes of depression which occurred 45 and 20 years ago, respectively. Both the episodes fully resolved with treatment, and the patient had no residual depressive symptoms in between the episodes. He also had severe nicotine dependence (smokeless tobacco) for about 56 years, from which he was abstinent for the previous year. The patient was treated with antidepressants for his second episode of depression along with trifluoperazine, 2 mg/day. After 1 month, his depressive symptoms resolved completely, and he stopped taking the antidepressants. However, he continued taking trifluoperazine in the same dose for the next 20 years. He said that if he ever tried to stop this medicine he felt very weak, restless, dysphoric, and had difficulty getting to sleep. But there was never any depressive cognition, guilty feeling, or other characteristic depressive symptoms. On days when he could not take this medicine, he experienced a craving for it. He and his family members felt that this was not normal and he tried to reduce the dose to 1 mg/day. Such attempts failed when he developed the above-mentioned symptoms the next day, which forced him to restart trifluoperazine, 2 mg/day. Symptoms resolved immediately every time thereafter. At times he started taking 3 mg/day, but generally he maintained a dosage of 2 mg/day. We treated the patient with escitalopram, 20 mg/day, for his depression and clonazepam, 1 mg/ day, for associated sleep problems which developed during this depressive episode. With this he showed marked improvement in depressive symptoms. He was, however, still continuing trifluoperazine and was not motivated to stop it. When we asked him to try abstinence from trifluoperazine, he said he was unable to do away with it.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Pharmacological therapy in progressive supranuclear palsy.

BACKGROUND To our knowledge, previous reports on drug treatment in progressive supranuclear palsy have not evaluated autopsy-confirmed cases. OBJECTIVE To evaluate pharmacological treatment responses from detailed clinical records in patients with autopsy-confirmed progressive supranuclear palsy. SUBJECTS AND METHODS We reviewed medical records for clinical presentation and pharmacological ...

متن کامل

Intraventricular tumor presenting as progressive supranuclear palsy-like phenotype.

A 70-year-old woman presented with a 2-year history of progressive difficulty in walking with frequent falls. Neurologic examination showed postural instability with backward falls, vertical supranuclear gaze palsy with normal vestibular-ocular reflex, rigidity, and pyramidal signs in the right limbs. There was no clinical response to levodopa. Laboratory serologic tests had normal results. MRI...

متن کامل

Amantadine-induced myoclonus in a patient with progressive supranuclear palsy.

Progressive supranuclear palsy (PSP) is a tauopathy that generally results in a hypokinetic disorder. Treatment is largely symptomatic, with some small studies indicating a benefit with dopaminergic therapy. Myoclonus is a hyperkinetic disorder that can be seen as part of later stage Parkinson's disease and in multiple system atrophy, but is rarely seen in PSP. Here we report a case of myoclonu...

متن کامل

Progressive supranuclear palsy: a brief personalized history.

Progressive supranuclear palsy (PSP) was originally described in 1964. Although some contended it was merely a variant of Parkinson's disease, a specific electron microscopic finding of straight, rather than twisted, filaments in the neurofibrillary tangles established PSP as a distinct entity. The almost pathognomonic early clinical finding of paralysis of downward gaze is due to lesions invol...

متن کامل

The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy.

Seven patients with progressive supranuclear palsy were treated with lisuride. Mean age was 62 years (range, 52 to 68 years), and duration of disease was 4.4 years (range, 1 to 7 years). All seven had been treated with levodopa/carbidopa and three with bromocriptine; four had, at one time, shown a partial response to levodopa. One patient had also shown a partial response to bromocriptine. Lisu...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • The Journal of neuropsychiatry and clinical neurosciences

دوره 20 4  شماره 

صفحات  -

تاریخ انتشار 2008